



July 2006

HELINN **N**NEWS

HELINN'S 2nd TIME AT
THE 12th INTERNATIONAL PAIN CLINIC CONGRESS,
THE WORLD SOCIETY OF PAIN CLINICIANS,
Turin, 4-7 July 2006

NIMESULIDE: A TOP-GEAR DRUG FOR THE TREATMENT OF PAIN AND INFLAMMATION

New evidences confirm the assets of Original Nimesulide: multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy

The 12th International Pain Clinic Congress organized by the World Society of Pain Clinicians was held in Turin (Italy) from 4 to 7 July last and Helsinn did not fail to be present with an *Exhibition Booth* and a very important Satellite Symposium titled "*A valuable common approach to the treatment of different pain conditions*".

The Congress was the right occasion to stake out the efficacy, rapidity of action and tolerability of Original Nimesulide in three major fields of application: osteoarthritis, post-operative dental pain and migraine and to bring for the first time to the attention of the scientific universe the active role played by Original Nimesulide on some key mediators involved in painful and inflammatory processes.

This was achieved through the organization of a Helsinn Satellite symposium with the following structure:



July 2006

HELINN NEWS



SCIENTIFIC PROGRAMME

Chairpersons

Hans G. KRESS

Dpt. of Anaesthesiology and Intensive Care Medicine B with Pain Center,
Medical University/AKH Wien – Austria

Giustino VARRASSI

Dpt. of Anaesthesiology University of L'Aquila - Italy

Mauro Bianchi

Dpt. of Pharmacology, Faculty of Medicine, University of Milan – Italy

Nimesulide and OA inflammatory pain: new clinical evidence

Adam Lörincz

Dpt. of Oral and Maxillofacial Surgery, Summelweis University Budapest – Hungary

Nimesulide and dental pain: results from an observational study

Christian Lampi

Dpt. of Neurology and Psychiatry, Pain and Headache Center, Linz General Hospital – Austria

Insights on the use of nimesulide in migraine attacks

The symposium, which registered the highest number of participants in comparison to the other sessions organized within the congress, was skillfully led by Professor H.G. Kress and Professor G. Varrassi who opened the symposium with an incisive overview on key nimesulide characteristics, which usefully put the topic



The speakers table



July 2006

HELINN NEWS

into context. The microphone then moved to Professor M. Bianchi who presented new clinical evidence on the analgesic and anti-inflammatory characteristics of nimesulide in osteoarthritis flare-ups, providing for the first time the proof of its unique activity on inflammatory pain mediators and confirming its faster and superior analgesic activity in comparison to the reference drug, celecoxib. Dr. Lörincz's presentation detailed interesting preliminary data from a new observational study involving more than 500 patients in 9 European dental clinics showing the superior efficacy of Original Nimesulide in granting complete resolution of pain versus other NSAIDs coupled with a fast acting profile. In the conclusive talk, Dr. Lampl provided a comprehensive overview on the current approach to migraine attacks, placing emphasis on the growing evidence of the widespread use of nimesulide in this painful condition.

At the booth, which was shared with Helsinn's Italian partner Novartis, attendees from all over the world had the opportunity to receive up-to-date information on the use of Original Nimesulide particularly in acute inflammatory pain conditions. In fact, the level of interest in our product was very high and extremely satisfactory.



Helsinn booth layout at the WSPC Congress

In conclusion, as brilliantly commented by Professor Kress, who closed a very interesting and lively symposium, we can affirm that also in this occasion ***Original Nimesulide proved, through several new pharmacological and clinical evidences, its up-to-date and unique multifaceted profile*** confirming once again that ***'Advance means progress to something better and not progress to something new!'***